Sumitovant is the parent company of five biopharmaceutical companies: Myovant, Urovant, Enzyvant, Altavant and Spirovant. Our companies have a robust pipeline of innovative drug treatments targeting a broad range of diseases. With a technology-enabled approach to drug discovery, development and commercialization, we remove friction from the process of bringing promising new compounds to market.
Sumitovant is wholly owned by Sumitomo Dainippon Pharma. Together, the Sumitomo Dainippon Pharma group of companies closely collaborate to expedite the discovery, development, and commercialization of truly innovative treatments. This collaboration harnesses the expertise of each organization with the goal of significantly improving patient outcomes and shareholder return.
